- Aspect Biosystems will lead development, manufacturing, and commercialization of cellular medicines for diabetes.
- Novo Nordisk will make an additional equity investment in Aspect and provide research funding.
- Aspect will integrate Novo Nordisk's cell therapy capabilities from the US and Denmark into its Canadian platform.
- Novo Nordisk retains rights to expand its role in later-stage development and commercialization.
Partnership Expansion
Aspect Biosystems and Novo Nordisk are advancing their collaboration to develop cellular medicines for diabetes. This new phase builds on their existing partnership, focusing on creating therapies that replace, repair, or supplement biological functions.
Roles and Responsibilities
Aspect Biosystems will lead the development, manufacturing, and commercialization of these therapies. Novo Nordisk retains the option to expand its role in later-stage development and commercialization.
Technological Integration
Aspect will integrate select manufacturing and R&D capabilities from Novo Nordisk's US and Denmark operations into its Canadian platform. This integration aims to enhance Aspect's end-to-end capabilities and access to skilled talent.
Financial and Strategic Investments
Novo Nordisk will make an additional equity investment in Aspect and provide research funding to advance the development of these therapies. The agreement includes potential royalties and milestone payments for Novo Nordisk based on future product sales.
